Skin patch for agitation in Alzheimer's dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in a care facility (like a nursing home or assisted living).
- You have a diagnosis of probable Alzheimer's disease.
- You have had at least two episodes of agitation in the past week that required help or caused problems.
- You score 23 or lower on a standard memory test (MMSE).
- You weigh more than 110 pounds and have a body mass index between 20 and 38.
- You haven't changed your regular medications in the last week, and some medications need to be stable for 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
This trial tests two different medications to quickly calm severe agitation in people admitted to a psychiatric emergency room. You may be able to join if you are extremely agitated and need urgent medication to help you settle down.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Hear when a new Agitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.